New tests of blood and spinal fluid can show how far Alzheimer’s has progressed and how fast a patient’s memory will decline.
Predicting cognitive decline in Alzheimer’s (Links to an external site)
New tests of blood and spinal fluid can show how far Alzheimer’s has progressed and how fast a patient’s memory will decline.
For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from the brains of people destined to develop Alzheimer’s dementia can delay the disease.
Clinical trial of people destined to develop early-onset Alzheimer’s disease shows eliminating amyloid from brain may prevent symptoms, supports need for confirmatory studies
Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression of symptoms in people with early-onset Alzheimer’s.
Study offers clues to treatment, prevention
Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer’s.
WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms arise
Study pegs certain cellular activities to driving Alzheimer’s disease. Researchers at Washington University School of Medicine in St. Louis have linked disease-related proteins and genes to identify specific cellular pathways responsible for Alzheimer’s genesis and progression.